• Immunostaining of tumors and precursor PanIN lesions from 4 week old LSL-KrasG12D; Cdkn2alox/lox; p48Cre (KIC) mice that were treated with 2G8 and/or gemcitabine, Gem. (Anti-Vimentin, cat. STJA0003823, green; Anti-E-cadherin, red). Photo courtesy of Rolf Brekken, University of Texas Southwestern. CC-BY-4. 0
  • Western blot of NIH 3T3 cell lysate showing specific immunolabeling of the ~50 kDa Vimentin protein.
  • Immunostaining of HeLa cells labelled with anti-vimentin antibody (cat. STJA0003823, 1:10,000, green) , anti-actin (red) , and DAPI (blue) labelling of nuclear DNA. The vimentin antibody labels the intermediate filament network while the actin antibody labels the submembranous cytoskeleton, stress fibers, and bundles of actin associated with cell adhesion sites.
  • Immunostaining of mixed neuron/glial cultures stained with anti-Vimentin antibody (STJA0003823, 1:500, green) and anti-GFAP antibody (cat. 620-GFAP, 1:1000, red). Vimentin is expressed alone in fibroblastic and endothelial cells, which are the flattened cells in the middle of the image which appear green. Astrocytes may express primarily GFAP, or GFAP and vimentin, and so appear red (GFAP only) or golden yellow (GFAP and Vimentin).

Anti-Vimentin antibody (STJA0003823)

SKU:
STJA0003823-100

£394.50
Shipping:
Free Shipping
Current Stock:
Host: Chicken
Applications: WB/IHC/ICC
Reactivity: Human/Mouse/Rat/Bovine/Canine/Feline/Goat/Guinea Pig/Hamster/Horse/Non-Human Primates/Rabbit/Sheep/Vole
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Chicken polyclonal antibody anti-Vimentin is suitable for use in Western Blot, Immunohistochemistry and Immunocytochemistry research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgY
Formulation: Total IgY fraction in PBS + 10 mM Sodium Azide.
Purification: This antibody was total igy fraction.
Dilution Range: WB 1:1000
IHC 1:500-1:5000
ICC 1:500-1:10, 000
IP
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: VIM
Gene ID: 7431
Uniprot ID: VIME_HUMAN
Immunogen: Recombinant human vimentin purification from E. coli.
Tissue Specificity Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.
Post Translational Modifications Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin. One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. Phosphorylated on tyrosine residues by SRMS. O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status. S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.
Function Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.
Protein Name Vimentin
Database Links Reactome: R-HSA-264870
Reactome: R-HSA-390522
Reactome: R-HSA-6785807
Reactome: R-HSA-9013422
Reactome: R-HSA-9613829
Reactome: R-HSA-9615710
Reactome: R-HSA-9646399
Cellular Localisation Cytoplasm
Cytoskeleton
Nucleus Matrix
Cell Membrane
Alternative Antibody Names Anti-Vimentin antibody
Anti-VIM antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance